Exelixis (EXEL) Acquisitions (2010 - 2011)
Exelixis' (EXEL) quarterly Acquisitions came in at $44000.0 in Q4 2011, down 89.0% year-on-year from $400000.0 in Q4 2010, and down 98.01% quarter-over-quarter from $2.2 million in Q3 2011.
Exelixis (EXEL) Acquisitions (2010 - 2011) Analysis & Trends
Exelixis' Acquisitions history runs 2 years deep, the most recent figure standing at $44000.0 for Q4 2011.
- On a quarterly basis, Acquisitions fell 89.0% year-over-year to $44000.0 in Q4 2011; TTM through Dec 2011 was $2.7 million, a N/A change from a year earlier, with the FY2011 full-year figure at $2.3 million, down 72.5% from the prior year.
- Acquisitions fell to $44000.0 in Q4 2011 per EXEL's latest filing, from $2.2 million in the prior quarter.
- Across five years, Acquisitions topped out at $3.3 million in Q2 2010 and bottomed at $44000.0 in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 44,000.00 |
| Sep 30, 2011 | 2.21 Mn |
| Dec 31, 2010 | 400,000.00 |
| Jun 30, 2010 | 3.30 Mn |